ASCO 2023 Update: This year's ASCO conference... - CLL Support
ASCO 2023 Update
You need to be a member of this community to see this post.
Read more about...
- Clinical trials
- Ibrutinib
- Rituximab
- Venetoclax
- Idelalisib
- Bendamustine
- Obinutuzumab
- Atezolizumab
- Acalabrutinib
4 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
End of suspense! Here is Dr. Koffman's ASCO 2020 "Top Pick" #1!
CLL Society's ASCO 2020 Conference Coverage. End of suspense! Here is Dr. Koffman's ASCO Top Pick...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
Oncology live May 06, 2020
The time-limited triplet of umbralisib, ublituximab, and venetoclax...
CLL Society Dr. Koffman's ASCO 2020 "Top 12" Picks #s 12, 11, 10
Dr. Koffman’s ASCO 2020 “Top 12” Picks
The 2020 Annual Meeting of the American Society of Clinical...
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO
Hi,
Just back from a frenetic and fantastic ASH, but still have news to share from ASCO.
But first...
Related Posts
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success- News about V+O and Acalabrutinib from EHA
- Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
This trial is going to reopen- Called CAPTIVATE. Ibrutinib plus venetoclax study sponsored by Pharmacyclics - Study Number PCYC-1142 . 
CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)
